Selective serotonin reuptake inhibitors (SSRIs) are among the most frequently prescribed medication classes in clinical practice. While they are generally considered safe and effective, clinicians should remain aware of several important drug interactions that can lead to clinically significant adverse effects. I will share my top 5 SSRI drug interactions.
CYP2D6 Inhibition: Paroxetine and Fluoxetine with Tamoxifen
One of the most clinically important SSRI interactions involves tamoxifen. Tamoxifen is a prodrug that requires activation through the CYP2D6 enzyme to produce its active metabolite. Certain SSRIs, particularly paroxetine and fluoxetine, are strong CYP2D6 inhibitors (excellent board exam nugget) and may reduce the conversion of tamoxifen into its active form. This interaction has raised concern about potentially decreasing tamoxifen’s effectiveness in patients being treated for estrogen receptor-positive breast cancer. When possible, clinicians often prefer alternatives with less CYP2D6 inhibition, such as sertraline, escitalopram, or venlafaxine.
Citalopram/Escitalopram and Proton Pump Inhibitors
Another commonly overlooked interaction involves citalopram or escitalopram used in combination with proton pump inhibitors (PPIs), particularly omeprazole and esomeprazole. These PPIs inhibit CYP2C19, an enzyme involved in the metabolism of citalopram and escitalopram. As a result, SSRI concentrations may increase, potentially raising the risk of QT prolongation. In higher-risk situations, clinicians may consider ECG monitoring, electrolyte assessment, or selection of alternative therapies.
SSRIs and Other Serotonergic Medications
Serotonin syndrome remains one of the most important pharmacodynamic interactions associated with SSRIs. Combining SSRIs with other serotonergic medications can lead to excessive serotonin activity within the central nervous system. Common interacting medications include tramadol, dextromethorphan, SNRIs, MAO inhibitors, linezolid, triptans, and even herbal products such as St. John’s Wort. Mild symptoms of serotonin syndrome may include tremor, anxiety, tachycardia, and diarrhea, while more severe presentations can involve hyperthermia, clonus, rigidity, and delirium.
Bleeding Risk with SSRIs
SSRIs are also associated with increased bleeding risk due to their effects on platelet aggregation. Platelets rely on serotonin uptake for normal hemostatic function, and SSRIs inhibit this process. While the absolute bleeding risk may be relatively small in many patients, the risk increases substantially when SSRIs are combined with medications that also increase bleeding potential. Common combinations of concern include SSRIs used alongside NSAIDs, aspirin, warfarin, direct oral anticoagulants such as apixaban or rivaroxaban, and antiplatelet medications like clopidogrel. .
Fluvoxamine
Among the SSRIs, fluvoxamine is often considered the medication with the greatest potential for clinically significant drug interactions. Fluvoxamine is a potent inhibitor of several CYP450 enzymes, particularly CYP1A2, CYP2C19, and to a lesser extent CYP3A4. Because of this, fluvoxamine can substantially increase serum concentrations of numerous medications. Some of the most important interactions include clozapine, olanzapine, warfarin, tizanidine, benzodiazepines, and caffeine. For example, fluvoxamine may dramatically increase tizanidine concentrations, leading to severe hypotension and sedation, while increased clozapine levels may raise the risk of seizures or toxicity. Patients taking fluvoxamine may also experience increased caffeine sensitivity due to reduced caffeine metabolism through CYP1A2 inhibition. Because of its extensive interaction profile, fluvoxamine often requires closer medication review and monitoring compared with other SSRIs, particularly in patients with polypharmacy.
Final Thoughts
SSRIs remain highly valuable medications in psychiatric and primary care practice, but clinicians should remain vigilant regarding important drug interactions. CYP-mediated interactions, serotonin syndrome risk, bleeding complications, QT prolongation, and fluvoxamine are among the most clinically relevant concerns encountered in practice. Careful medication review, patient counseling, and ongoing monitoring can substantially reduce the risk of preventable adverse effects associated with SSRI therapy.
0 Comments